Compounded Fluticasone useful in Eosinophilic esophagitis, finds study
In a recently published study in Diseases of the Esophagus,researchers have highlighted that Compounded fluticasone should be considered as an EoE management option.
Eosinophilic esophagitis (EoE) has a spectrum of presenting symptoms, including feeding difficulties, failure to thrive, vomiting, epigastric and chest pain, dysphagia and food impactions. Clinical experience and increasing evidence suggests that these symptoms may develop chronologically. Treatment options available for patients with EoE include dietary management and/or pharmacologic therapy. An individualized approach to treatment is preferred, with an emphasis on patient–parental preference.
To date,No approved medication exists for the treatment of eosinophilic esophagitis (EoE) in the United States, which forces patients to utilize off-label drugs and/or create their own formulations.
Therefore, researchers assessed the efficacy of a standardized compounded fluticasone suspension. To do this, they performed a retrospective cohort study identifying all EoE patients treated with compounded fluticasone. Compounded fluticasone was prescribed during routine clinical care and dispensed by a specialty compounding pharmacy.
Clinical data were extracted from medical records. Outcomes (symptomatic, endoscopic, and histologic) were assessed after the initial and last compounded fluticasone treatment in our system. There were 27 included patients (mean age 34.2; 67% male; 96% white) treated for a mean length of 5.4 ± 4.4 months. The majority (89%) previously utilized dietary elimination or topical corticosteroids, and many (75%) had primary non-response or secondary loss of response to these treatments.
Data analysis revealed the following facts.
- After starting compounded fluticasone, symptoms and endoscopic findings improved [dysphagia (89 vs. 56%, P = 0.005), food impaction (59 vs. 4%, P = 0.003), heartburn (26 vs. 4%, P = 0.01), chest pain (26 vs. 8%, P = 0.05), white plaques (63 vs. 32%; P = 0.005), furrows (81 vs. 60%; P = 0.06), and edema (15 vs. 4%; P = 0.16)].
- The median of the peak eosinophil counts decreased from 52 to 37 eos/hpf (P = 0.10) and 35% of patients achieved <15 eos/hpf. In conclusion, compounded fluticasone provided a significant improvement in symptoms and endoscopic findings, with more than a third achieving histologic response in a treatment refractory EoE population.
For the full aticle follow the link: 10.1093/dote/doaa120
Primary source: Diseases of the Esophagus
